Log In Sign up
The largest database of trusted experimental protocols

Nk1.1 buv395

Manufactured by BD
Visit Supplier

NK1.1 BUV395 is a fluorescently-labeled monoclonal antibody designed for flow cytometry applications. It binds to the NK1.1 antigen expressed on natural killer (NK) cells and a subset of T cells in mice.

Automatically generated - may contain errors

Lab products found in correlation

Ly6g pe, by BioLegend (3 mentions) Cd4 buv805, by BD (3 mentions) Cd3εbuv395, by BD (3 mentions) Cd8a bv785, by BioLegend (3 mentions) Epcam apc af647, by BioLegend (3 mentions) Cd11c buv737, by BD (3 mentions) Ly6c bv785, by BioLegend (3 mentions) Cd11b bv650, by BioLegend (3 mentions) F4 80 bv421 pb, by BioLegend (3 mentions) Cd68 apc cy7, by BioLegend (3 mentions) Cd19 fitc, by BioLegend (3 mentions) Anti mouse cd16 cd32 fc block, by BioLegend (3 mentions) Zombie aqua fixable viability kit, by BioLegend (3 mentions) Cd45 percp cy5, by BioLegend (3 mentions) Tumor dissociation kit, by Miltenyi Biotec (2 mentions) Tcr γδ bv421, by BioLegend (1 mentions) Cd25 bv650, by BioLegend (1 mentions) Cd62l pe, by BioLegend (1 mentions) Lsrfortessa, by BD (1 mentions)

3 protocols using nk1.1 buv395

1

Simultaneous Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fresh tumor samples were minced and enzymatically digested with the tumor dissociation kit (Miltenyi #130-096-730) for 40 min at 37°C with agitation. The cell suspension was strained through a 100 μm strainer, spun down and resuspended in 2% FCS/PBS. Cells were blocked for 10 min on ice with anti-mouse CD16/CD32 FC block (Biolegend, 1:100) and stained with Zombie Aqua Fixable Viability Kit (Biolegend, 1:500) and the following antibody cocktails: CD4 BUV805 (BD, 1:100), CD3εBUV395 (BD, 1:20), CD8a BV785 (Biolegend, 1:100), CD45 PerCP Cy5.5 (Biolegend, 1:100), CD19 FITC (Biolegend, 1:100), EpCAM APC/AF647 (Biolegend, 1:200) for acquisition of adaptive immune cells; CD11c BUV737 (BD, 1:30), NK1.1 BUV395 (BD, 1:25), Ly6C BV785 (Biolegend, 1:200), CD11b BV650 (Biolegend, 1:100), F4/80 BV421/PB (Biolegend, 1:30), CD45 PerCP Cy5.5 (Biolegend, 1:100), Ly6G PE (Biolegend, 1:200), CD68 APC-CY7 (Biolegend, 1:20), EpCAM APC/AF647 (Biolegend, 1:200) for acquisition of innate immune cells. Per panel 1,000,000 events were acquired on the BD LSRFortessa. Flow cytometry data was analyzed using FlowJo software (v10.6.2).
Falcomatà C., Bärthel S., Widholz S.A., Schneeweis C., Montero J.J., Toska A., Mir J., Kaltenbacher T., Heetmeyer J., Swietlik J.J., Cheng J.Y., Teodorescu B., Reichert O., Schmitt C., Grabichler K., Coluccio A., Boniolo F., Veltkamp C., Zukowska M., Vargas A.A., Paik W.H., Jesinghaus M., Steiger K., Maresch R., Öllinger R., Ammon T., Baranov O., Robles M.S., Rechenberger J., Kuster B., Meissner F., Reichert M., Flossdorf M., Rad R., Schmidt-Supprian M., Schneider G, & Saur D. (2022). Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nature cancer, 3(3), 318-336.
+ Open protocol
+ Expand
2

Multiparametric Flow Cytometry of Tumor Immune Cells

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Dissociation of fresh tumor samples and antibody staining was performed as described previously40 (link). Cells were blocked with anti-mouse CD16/CD32 FC block (Biolegend, 1:100) for 10 min on ice and stained with Zombie Aqua Fixable Viability Kit (Biolegend, 1:500) to discriminate live and dead cells. The following antibody cocktails were used: CD4 BUV805 (BD, 1:100), CD3εBUV395 (BD, 1:20), CD8a BV785 (Biolegend, 1:100), CD25 BV650 (Biolegend, 1:50), TCRγ/δ BV421 (Biolegend, 1:100), CD62L PE (Biolegend, 1:500), CD44 APC-Fire (Biolegend, 1:30), CD45 PerCP Cy5.5 (Biolegend, 1:100), CD19 FITC (Biolegend, 1:100), EpCAM APC/AF647 (Biolegend, 1:200) for acquisition of adaptive immune cells; CD11c BUV737 (BD, 1:30), NK1.1 BUV395 (BD, 1:25), Ly6C BV785 (Biolegend, 1:200), CD11b BV650 (Biolegend, 1:100), F4/80 BV421/PB (Biolegend, 1:30), CD45 PerCP Cy5.5 (Biolegend, 1:100), Ly6G PE (Biolegend, 1:200), CD68 APC-CY7 (Biolegend, 1:20), EpCAM APC/AF647 (Biolegend, 1:200) for acquisition of innate immune cells. 1 × 106  events were acquired per antibody panel on the BD LSRFortessa. Flow cytometry data were analyzed using FlowJo software (v10.6.2).
Swietlik J.J., Bärthel S., Falcomatà C., Fink D., Sinha A., Cheng J., Ebner S., Landgraf P., Dieterich D.C., Daub H., Saur D, & Meissner F. (2023). Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation. Nature Communications, 14, 2642.
+ Open protocol
+ Expand
3

Simultaneous Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fresh tumor samples were minced and enzymatically digested with the tumor dissociation kit (Miltenyi #130-096-730) for 40 min at 37°C with agitation. The cell suspension was strained through a 100 μm strainer, spun down and resuspended in 2% FCS/PBS. Cells were blocked for 10 min on ice with anti-mouse CD16/CD32 FC block (Biolegend, 1:100) and stained with Zombie Aqua Fixable Viability Kit (Biolegend, 1:500) and the following antibody cocktails: CD4 BUV805 (BD, 1:100), CD3εBUV395 (BD, 1:20), CD8a BV785 (Biolegend, 1:100), CD45 PerCP Cy5.5 (Biolegend, 1:100), CD19 FITC (Biolegend, 1:100), EpCAM APC/AF647 (Biolegend, 1:200) for acquisition of adaptive immune cells; CD11c BUV737 (BD, 1:30), NK1.1 BUV395 (BD, 1:25), Ly6C BV785 (Biolegend, 1:200), CD11b BV650 (Biolegend, 1:100), F4/80 BV421/PB (Biolegend, 1:30), CD45 PerCP Cy5.5 (Biolegend, 1:100), Ly6G PE (Biolegend, 1:200), CD68 APC-CY7 (Biolegend, 1:20), EpCAM APC/AF647 (Biolegend, 1:200) for acquisition of innate immune cells. Per panel 1,000,000 events were acquired on the BD LSRFortessa. Flow cytometry data was analyzed using FlowJo software (v10.6.2).
Falcomatà C., Bärthel S., Widholz S.A., Schneeweis C., Montero J.J., Toska A., Mir J., Kaltenbacher T., Heetmeyer J., Swietlik J.J., Cheng J.Y., Teodorescu B., Reichert O., Schmitt C., Grabichler K., Coluccio A., Boniolo F., Veltkamp C., Zukowska M., Vargas A.A., Paik W.H., Jesinghaus M., Steiger K., Maresch R., Öllinger R., Ammon T., Baranov O., Robles M.S., Rechenberger J., Kuster B., Meissner F., Reichert M., Flossdorf M., Rad R., Schmidt-Supprian M., Schneider G, & Saur D. (2022). Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nature cancer, 3(3), 318-336.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!